BRPI0812430A2 - Uso do fator do crescimento de fibroblasto 7 (fgf7) e do receptor fgfr2b como biomarcadores. - Google Patents

Uso do fator do crescimento de fibroblasto 7 (fgf7) e do receptor fgfr2b como biomarcadores.

Info

Publication number
BRPI0812430A2
BRPI0812430A2 BRPI0812430-2A2A BRPI0812430A BRPI0812430A2 BR PI0812430 A2 BRPI0812430 A2 BR PI0812430A2 BR PI0812430 A BRPI0812430 A BR PI0812430A BR PI0812430 A2 BRPI0812430 A2 BR PI0812430A2
Authority
BR
Brazil
Prior art keywords
fgfr2b
fgf7
biomarkers
receiver
growth factor
Prior art date
Application number
BRPI0812430-2A2A
Other languages
English (en)
Inventor
Jens Hoffmann
Daniel Korr
Jan Kunde
Anette Sommer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0812430A2 publication Critical patent/BRPI0812430A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0812430-2A2A 2007-06-08 2008-06-05 Uso do fator do crescimento de fibroblasto 7 (fgf7) e do receptor fgfr2b como biomarcadores. BRPI0812430A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007026877A DE102007026877A1 (de) 2007-06-08 2007-06-08 Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker
US94415307P 2007-06-15 2007-06-15
PCT/EP2008/004675 WO2008148582A1 (en) 2007-06-08 2008-06-05 Use of fibroblast growth factor 7 (fgf7) and of the receptor fgfr2b as biomarkers

Publications (1)

Publication Number Publication Date
BRPI0812430A2 true BRPI0812430A2 (pt) 2014-10-29

Family

ID=39942207

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812430-2A2A BRPI0812430A2 (pt) 2007-06-08 2008-06-05 Uso do fator do crescimento de fibroblasto 7 (fgf7) e do receptor fgfr2b como biomarcadores.

Country Status (16)

Country Link
US (1) US20080311594A1 (pt)
EP (1) EP2156192A1 (pt)
JP (1) JP2010530523A (pt)
KR (1) KR20100017683A (pt)
CN (1) CN101688870A (pt)
AR (1) AR066893A1 (pt)
AU (1) AU2008258805A1 (pt)
BR (1) BRPI0812430A2 (pt)
CA (1) CA2688480A1 (pt)
DE (1) DE102007026877A1 (pt)
IL (1) IL201678A0 (pt)
MX (1) MX2009013167A (pt)
RU (1) RU2009149014A (pt)
TW (1) TW200908993A (pt)
WO (1) WO2008148582A1 (pt)
ZA (1) ZA201000132B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911491A2 (pt) * 2008-04-29 2016-01-05 Novartis Ag métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos.
WO2011025814A1 (en) * 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury
RU2012148816A (ru) * 2010-05-07 2014-06-20 Ф. Хоффманн-Ля Рош Аг Метод диагностики для определения клеток ex vivo
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
JP2018517136A (ja) * 2015-05-14 2018-06-28 エクスプレッション、パソロジー、インコーポレイテッドＥｘｐｒｅｓｓｉｏｎ Ｐａｔｈｏｌｏｇｙ， Ｉｎｃ． 線維芽細胞増殖因子受容体２（ｆｇｆｒ２）タンパク質のためのｓｒｍ／ｍｒｍアッセイ
CN111760026B (zh) * 2020-08-06 2026-04-03 汪炬 FGFR2b抑制分子在制备治疗PAF介导的疾病药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1137945A1 (en) * 1998-12-08 2001-10-04 Board of Regents, The University of Texas System Methods for detection of antiestrogen-resistant breast cancer
ES2240430T3 (es) * 2000-03-20 2005-10-16 Pfizer Products Inc. Tratamiento combinado con factor de crecimiento de queratinocitos e inhibidor del factor de crecimiento epidermico.
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
US20090105463A1 (en) * 2005-03-29 2009-04-23 Massachusetts Institute Of Technology Compositions of and Methods of Using Oversulfated Glycosaminoglycans
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP1951336A2 (en) * 2005-07-18 2008-08-06 The Trustees Of Boston University Method to inhibit proliferation and growth of metastases
NZ565511A (en) * 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins

Also Published As

Publication number Publication date
WO2008148582A1 (en) 2008-12-11
TW200908993A (en) 2009-03-01
EP2156192A1 (en) 2010-02-24
AU2008258805A1 (en) 2008-12-11
ZA201000132B (en) 2011-03-30
AR066893A1 (es) 2009-09-16
CA2688480A1 (en) 2008-12-11
US20080311594A1 (en) 2008-12-18
DE102007026877A1 (de) 2008-12-11
IL201678A0 (en) 2010-05-31
KR20100017683A (ko) 2010-02-16
MX2009013167A (es) 2010-01-15
JP2010530523A (ja) 2010-09-09
RU2009149014A (ru) 2011-07-20
CN101688870A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0807699A2 (pt) Receptor sps com linearidade ajustável.
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0821668A2 (pt) Uso
BRPI0919193A2 (pt) Uso de lipídeo, e, composição nutricional
MX301032B (es) Acetales de levuminato de glicerol y su uso
FR2943680B1 (fr) Composition de caoutchoux et pneumatique utilisant cette composition.
CR10689A (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano
BRPI0915086A2 (pt) detecção do uso de canabis
BRPI0923500A2 (pt) uso e composição farmacêutica compreendendo agonista ou modulador do receptor s1p, e kit.
BRPI0820184A2 (pt) Agente de aperfeiçoamento do solo e uso do mesmo.
BRPI0924177A2 (pt) Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso
BRPI0814420A2 (pt) composição, e, uso de álcool alcoxilado.
BRPI0911563A2 (pt) uso de antagonista da progesterona
BRPI0823082A2 (pt) Uso derivados de sesquiterpeno
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
BRPI0907365A2 (pt) Composição antimicrobiana e uso
BRPI0920953A2 (pt) dispositivo de manutenção, e uso do mesmo.
BRPI0923015A2 (pt) enxertos ósseos com atividade de protease reduzida e métodos de seleção e uso
BRPI0919216A2 (pt) poliuretano, e, uso de um poliuretano
BRPI0913175A2 (pt) artigo antibalístico, e, uso do mesmo.
BRPI0818641A2 (pt) Rótulo, e, uso do rótulo
BRPI0817974A2 (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas.
BRPI0921044A2 (pt) composto heterocíclico de acenafto, composto de inclusão de ciclodextrina do composto heterocíclico de acenafto, complexo de ciclodextrina do composto heterocíclico de acenafto, uso do composto heterocíclico de acenafto, uso do composto de inclusão de ciclodextrina do composto heterocíclico de acenafto e uso do complexo de ciclodextrina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]